Pharmacologic therapy of patients with pituitary tumors secreting prolactin, growth hormone and adrenocorticotropin.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000324:Adrenocorticotropic Hormone / Q000378:metabolism*; D000568:Amenorrhea / Q000209:etiology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use; D003533:Cyproheptadine / Q000627:therapeutic use; D004873:Ergolines / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D005687:Galactorrhea / Q000209:etiology; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D007031:Hypothalamus / Q000503:physiopathology; D007980:Levodopa / Q000627:therapeutic use; D010902:Pituitary Gland / Q000503:physiopathology; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011247:Pregnancy; D011388:Prolactin / Q000378:metabolism*
D000317:Adrenergic alpha-Antagonists; D000970:Antineoplastic Agents; D004873:Ergolines; D004967:Estrogens; D003533:Cyproheptadine; D001971:Bromocriptine; D007980:Levodopa; D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D013006:Growth Hormone